Lineage Cell Therapeutics Inc [LCTX] stock prices are up 0.51% to $0.95 at the moment. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The LCTX shares have gain 12.35% over the last week, with a monthly amount glided 10.45%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Lineage Cell Therapeutics Inc [AMEX: LCTX] stock has seen the most recent analyst activity on August 20, 2024, when Craig Hallum initiated its Buy rating and assigned the stock a price target of $4. Previously, Robert W. Baird started tracking the stock with Outperform rating on November 02, 2022, and set its price target to $5. On June 14, 2022, B. Riley Securities initiated with a Buy rating and assigned a price target of $4 on the stock. Noble Capital Markets started tracking the stock assigning a Outperform rating and suggested a price target of $8 on August 19, 2021. Cantor Fitzgerald initiated its recommendation with a Overweight and recommended $6 as its price target on March 31, 2021.
The stock price of Lineage Cell Therapeutics Inc [LCTX] has been fluctuating between $0.77 and $1.61 over the past year. Lineage Cell Therapeutics Inc [AMEX: LCTX] shares were valued at $0.95 at the most recent close of the market.
Analyzing the LCTX fundamentals
The Lineage Cell Therapeutics Inc [AMEX:LCTX] reported sales of 6.19M for trailing twelve months, representing a drop of -56.34%. Gross Profit Margin for this corporation currently stands at 0.83% with Operating Profit Margin at -4.14%, Pretax Profit Margin comes in at -3.91%, and Net Profit Margin reading is -3.91%. To continue investigating profitability, this company’s Return on Assets is posted at -0.24, Equity is -0.36 and Total Capital is -0.29. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.02.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 0.9293 points at the first support level, and at 0.9097 for the second support level. However, for the 1st resistance point, the stock is sitting at 0.9692, and for the 2nd resistance point, it is at 0.9895.
Ratios To Look Out For
It’s worth pointing out that Lineage Cell Therapeutics Inc [AMEX:LCTX]’s Current Ratio is 2.64. Further, the Quick Ratio stands at 2.64, while the Cash Ratio is 1.94. Considering the valuation of this stock, the price to sales ratio is 28.94, the price to book ratio is 2.62.
Transactions by insiders
Recent insider trading involved Howe Jill Ann, Chief Financial Officer, that happened on Aug 16 ’24 when 10500.0 shares were purchased. President and CEO, Culley Brian M completed a deal on May 24 ’24 to buy 10000.0 shares. Meanwhile, Director BAILEY DON M bought 96155.0 shares on Feb 08 ’24.
